CTKB - Company ID 0001831915
The table below shows Cytek Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $201.49M | $200.45M | $193.01M | $2.96M | $2.18M | $710.00K |
| Cost of revenue | $97.03M | $89.35M | $83.59M | $63.06M | $48.81M | $41.13M |
| Gross profit | $104.46M | $111.11M | $109.43M | $100.97M | $79.14M | $51.71M |
| R&D | $36.47M | $39.40M | $44.15M | $34.86M | $24.44M | $13.69M |
Cytek Biosciences, Inc. reported annual revenue of $201.49M for fiscal year 2025. That is up 0.5% from $200.45M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $710.00K (FY 2020) to $201.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $58.94M |
| $43.11M |
| $43.97M |
| $34.69M |
| $20.84M |
| $9.37M |
| Operating income | -$40.38M | -$20.52M | -$27.84M | -$1.80M | $9.16M | $13.66M |
| Income tax | $36.70M | $320.00K | -$3.56M | -$1.22M | $2.91M | -$4.98M |
| Net income | -$66.54M | -$6.02M | -$12.15M | $2.48M | $3.03M | $19.41M |
| EPS (diluted) | - | - | -$0.09 | $0.02 | $0.00 | $0.10 |